康龙化成:2025年H股奖励信托计划

Pharmaron Beijing Co., Ltd.
康龙化成（北京）新药技术股份有限公司
2025 H Share Award and Trust Scheme
2025年H股奖励信托计划

Table of Contents 目录

1. Definitions and Interpretation 定义和解释 ...... 1
2. General Introduction and Purpose of the Scheme 本计划概览与目的...... 5
3. Conditions 条件...... 7
4. Duration 期限 ...... 7
5. Administration 管理 ...... 7
6. Selection of Selected Participant 选定参与者的选择...... 10
7. Award Letter regarding Grant of Awards 奖励授予的奖励函 ...... 15
8. Receipt of Treasury H Shares by the Trustee 受托人接受库存H股股票的转让...... 15
9. Granting and Vesting of Award 奖励的授予及归属 ...... 16
10. Changes of Circumstances Pertaining to the Selected Participants and Clawback Mechanism 选定参
与者的情况变化及回拨机制 ...... 20
11. Transferability and Other Rights to Award Shares 授予股票的转让及其他权利 ...... 23
12. Interest in the Assets of the Trust 信托资产权益 ...... 24
13. Restrictive Covenants 限制性条款 ...... 25
14. Takeover, Rights Issue, Open Offer, Scrip Dividend Scheme, etc. 收购、配股、公开发售、股票
分红计划等 ...... 26
Change in control 控制权变更 ...... 26
Open offer and rights issue 公开发行和配股 ...... 26
Bonus warrants 红利认股权证 ...... 26
Scrip dividend 股票股利 ...... 26
Consolidation, sub-division, capitalization issue 合并、分立、资本化发行...... 27
Voluntary winding-up 自动清盘 ...... 28
Compromise or arrangement 和解或偿债安排 ...... 28
15. Scheme Mandate Limit 计划授权上限 ...... 29
16. Returned Shares 退还股票 ...... 31
17. Interpretation 解释...... 31
18. Amendment of the Scheme 方案修订...... 31
19. Cancellation of Awards 取消奖励...... 32
20. Termination 计划终止...... 32
21. Miscellaneous 其他条款 ...... 33
22. Dispute Resolution 争议解决 ...... 36
23. Governing law 适用法律...... 36
24. Translation 翻译 ...... 36
1. Definitions and Interpretation 定义和解释
1.1 In these Scheme Rules, unless the context otherwise requires, each of the following words and
expressions shall have the meaning respectively shown opposite to it:
在本计划中，除非文中另有所指，释义如下：
“Actual Selling Price” is the actual price at which the Awards Shares are sold (net of brokerage,
Stock Exchange trading fee, SFC transaction levy and any other applicable costs) on vesting of an
Award pursuant to the Scheme or in the case of a vesting when there is an event of change in
control or privatisation of the Company pursuant to Rule 14.1, the consideration receivable under
the related scheme or offer;
“实际售价”指根据本计划在奖励股票归属后出售该等股票的实际价格（扣除经纪费、证券
交易所交易费、证监会交易征费及任何其他适用费用后），或在根据第14.1条规定公司控
制权变动或私有化发生时归属，相关计划或要约下的应收对价；
“Adoption Date” is the date on which the Shareholders and the Board approve this Scheme (i.e.
June 20, 2025);
“采纳日期”指股东和董事会审议通过本计划之日 (即2025年6月 20日)；
“Articles” is the articles of association of the Company as amended from time to time;
“章程”指经不时修订的公司章程；
“associate” shall have the meaning as set out in the Listing Rules;
“联系人” 的定义见《上市规则》的规定；
“Award” is an award granted by a Delegatee to a Selected Participant, pursuant to the Scheme,
which may vest in the form of Award Shares or the Actual Selling Price of the Award Shares in
cash, as such Delegatee may determine in accordance with the terms of the Scheme Rules. For the
avoidance of doubt, any award granted under this Scheme shall not involve the issuance or grant
of any options or other similar rights;
“奖励”指授权人士根据本计划对选定参与者授予的奖励，由授权人士根据本计划条款约
定，以奖励股票或用现金支付奖励股票的实际售价的形式实现归属。为免生疑问，根据本
计划授出的任何奖励不得涉及发行或授予任何期权或其他类似权利；
“Award Letter” shall have the meaning as set out in Rule 7.1;
“奖励函”的定义参见本计划第7.1条；
“Award Period”is the period commencingon the Adoption Date, and endingon the Business Day
immediately prior to the 10th anniversary of the Adoption Date;
“奖励期限”指从采纳日期起至采纳日期届满 10 周年前的最后一个交易日止的期间；
“Award Shares” is the H Shares granted to a Selected Participant in an Award;
“奖励股票”指对选定参与者奖励时向其授予的H股股票；
“Board” is the board of directors of the Company (please also refer to Rule 1.2(i)), from time to
time;
“董事会”本公司的董事会（另请参阅第1.2（i）条）；

“Business Day” is any day on which the Stock Exchange is open for the business of dealing in
securities;
“交易日”指联交所开放证券交易业务的任何一天；
“Company” or “our Company” is Pharmaron Beijing Co., Ltd.;
“公司”或“本公司”指康龙化成（北京）新药技术股份有限公司；
“connected person” shall have the meaning as set out in the Listing Rules;
“关连人士”的定义参见《上市规则》；
“Delegatee” is the Management Committee, person(s) or board committee(s) to which the Board
has delegated its authority;
“授权人士”指董事会授权的管理委员会、人员或董事会下属委员会；
“Director(s)” is the director(s) of the Company, from time to time;
“董事”指本公司不时在任的董事；
“Eligible Employee” shall have the meaning as set out in Rule 6.1; however, no individual who is
resident in a place where the grant, acceptance or vesting of an Award pursuant to the Scheme is
not permitted under the laws and regulations of suc